The WHO said that case numbers last week were on the rise in several countries in the Americas and it stressed that a slowdown worldwide in new cases could be the “most dangerous” time in the outbreak.
WHO chief Tedros Adhanom Ghebreyesus said more than 70,000 cases have now been reported to the U.N. health agency this year, with 26 deaths.
“Globally, cases are continuing to decline, but 21 countries in the past week reported an increase in cases, mostly in the Americas, which accounted for almost 90 percent of all cases reported last week,” he told a press conference in Geneva.
Real-world data (and real-world evidence) can also play roles outside of public health emergencies like Covid and monkeypox. They can help determine the long-term effectiveness of many treatments, especially those subject to the expedited approval process, such as those used for rare diseases, and can help determine the value of drugs in general. In many cases, clinical trials are not enough to understand how well drugs really work. Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research, has said that the clinical trial system is “broken” and that more use of real-world evidence could be an effective addition to the approval process.
The FDA has been taking steps toward using more real-world data outside of public health emergencies like Covid and monkeypox. In 2018, the agency issued guidance for use of such evidence in approving drugs. By 2021, when the FDA issued enhanced guidance on the topic, real-world evidence had been used in approving 90 medical devices and the new use of a drug, Prograf. But this is not happening enough in practice.
Failing to use real-world data means missing out not just on better understanding of the effectiveness of individual drugs but also on a chance to improve the entire pharmaceutical sector, including addressing issues like rising costs. The availability of more data on real-world outcomes from using drugs, especially gene therapies and other innovative and often very expensive treatments, would pave the way for pricing to take patient outcomes into account through approaches like value-based contracting, when health insurers base drug prices on how well drugs work in the people who take them, rather than just in premarket clinical trials.
An interdisciplinary team of researchers has developed a blueprint for creating algorithms that more effectively incorporate ethical guidelines into artificial intelligence (AI) decision-making programs. The project was focused specifically on technologies in which humans interact with AI programs, such as virtual assistants or “carebots” used in healthcare settings.
“Technologies like carebots are supposed to help ensure the safety and comfort of hospital patients, older adults and other people who require health monitoring or physical assistance,” says Veljko Dubljević, corresponding author of a paper on the work and an associate professor in the Science, Technology & Society program at North Carolina State University. “In practical terms, this means these technologies will be placed in situations where they need to make ethical judgments.”
“For example, let’s say that a carebot is in a setting where two people require medical assistance. One patient is unconscious but requires urgent care, while the second patient is in less urgent need but demands that the carebot treat him first. How does the carebot decide which patient is assisted first? Should the carebot even treat a patient who is unconscious and therefore unable to consent to receiving the treatment?”
In an effort to streamline the process of diagnosing patients with multiple sclerosis and Parkinson’s disease, researchers used digital cameras to capture changes in gait—a symptom of these diseases—and developed a machine-learning algorithm that can differentiate those with MS and PD from people without those neurological conditions.
Their findings are reported in the IEEE Journal of Biomedical and Health Informatics.
The goal of the research was to make the process of diagnosing these diseases more accessible, said Manuel Hernandez, a University of Illinois Urbana-Champaign professor of kinesiology and community health who led the work with graduate student Rachneet Kaur and industrial and enterprise systems engineering and mathematics professor Richard Sowers.
New York Gov. Kathy Hochul has extended the state of emergency declared in response to the spread of poliovirus after sewage tested positive in Brooklyn and Queens.
Hochul said the state disaster emergency will remain in place at least through Nov. 8 to support statewide efforts to boost the vaccination rate against polio.
The New York State Department of Health, in a statement Tuesday, said the sewage sample that tested positive in Brooklyn and Queens is genetically linked to the virus that paralyzed an unvaccinated adult in Rockland County over the summer.
So early to bed early to rise does not necessarily make a person healthy wealthy and wise.
In a recent study, scientists found early sleeping had a 70% higher risk of developing dementia.
Sleep may impact both physical and mental health and has been linked to various health conditions such as heart disease, stroke, dementia, depression, and obesity.
On September 21, researchers published a study in the Journal of the American Geriatrics Society, which shows early sleeping had a 70% higher risk of developing dementia and cognitive decline.
While CommonSpirit declined to share specifics, a person familiar with its remediation efforts confirmed to NBC News that it had sustained a ransomware attack.
CommonSpirit, which has more than 140 hospitals in the U.S., also declined to share information on how many of its facilities were experiencing delays. Multiple hospitals, however, including CHI Memorial Hospital in Tennessee, some St. Luke’s hospitals in Texas, and Virginia Mason Franciscan Health in Seattle all have announced they were affected.
Dr. Sarita A. Mohanty, MD, MPH, MBA (https://www.thescanfoundation.org/about/board-of-directors/sarita-a-mohanty/), serves as the President and Chief Executive Officer of The SCAN Foundation, one of the largest foundations in the United States focused on improving the quality of health and life for older adults. Its mission is to advance a coordinated and easily navigated system of high-quality services for older adults that preserve dignity and independence.
The SCAN Foundation was created as an independent charitable organization in April 2008 through a $205 Million one-time contribution from the not-for-profit SCAN Health Plan, a not-for-profit, Medicare Advantage based in Long Beach, California.
Previously, Dr. Mohanty served as the Vice President of Care Coordination for Medicaid and Vulnerable Populations at Kaiser Permanente; Assistant Professor of Medicine at USC; Chief Medical Officer of COPE Health Solutions, a health care management consulting company; and Senior Medical Director at L.A. Care, the largest U.S. public health plan.
Dr. Mohanty completed her Internal Medicine residency at Beth Israel Deaconess Medical Center and research fellowship at Harvard Medical School. She earned her MD from Boston University, MPH from Harvard University, and MBA from UCLA. She completed undergraduate work at UC Berkeley. She currently is an Associate Professor at the Kaiser Permanente Bernard J. Tyson School of Medicine and is a practicing internal medicine physician with Kaiser Permanente.
How we got to where we are today, and where we go from here. Featuring Dr. Daniel Monti (Director — Marcus Institute of Integrative Health) and leading neuroscientist Dr. Andrew Newberg (DMT: The Spirit Molecule), we get a fresh perspective on the effects of stress. Thanks to a new study from the Marcus Institute of Integrative Health at Thomas Jefferson University in Philadelphia, PA, there is now compelling evidence that this breakthrough intervention can help people to alleviate their emotional stress, as well as deeper insight into this exciting topic.
Two groundbreaking studies recently published in the journals Nature and Genome Medicine found genetic signatures that explain ethnic disparities in the severity of prostate cancer, notably in Sub-Saharan Africa.
By genetically analyzing prostate cancer tumors from Australian, Brazilian, and South African donors, the team developed a new prostate cancer taxonomy (classification scheme) and cancer drivers that not only distinguish patients based on their genetic ancestry but also predict which cancers are likely to become life-threatening, a task that is currently difficult.
“Our understanding of prostate cancer has been severely limited by a research focus on Western populations,” said senior author Professor Vanessa Hayes, genomicist and Petre Chair of Prostate Cancer Research at the University of Sydney’s Charles Perkins Centre and Faculty of Medicine and Health in Australia. “Being of African descent, or from Africa, more than doubles a man’s risk for lethal prostate cancer. While genomics holds a critical key to unraveling contributing genetic and non-genetic factors, data for Africa has till now, been lacking.”
